Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/266154 
Year of Publication: 
2022
Series/Report no.: 
ARTNeT Working Paper Series No. 217
Publisher: 
Asia-Pacific Research and Training Network on Trade (ARTNeT), Bangkok
Abstract: 
The coronavirus disease (COVID-19) pandemic has highlighted the crucial role of vaccines in public health management and economic recovery. Its worldwide impact has raised national security concerns and implications on health policies, particularly on Asia Pacific countries' readiness to cope with the next pandemic. This report explains the rise of COVID-19 vaccine production of key vaccines and differentiates them into two different approaches: the internalization-driven production, in which the leading pharmaceutical multinationals control most of the vaccine production in a few locations; and the externalization-driven production, whereby lead companies extend their vaccine production to various regions. These two approaches are led by various factors, including vaccine technology, strategy and missions of the vaccine producers, and the availability and capacity of qualified contract manufacturers in host countries. Pros and cons for each approach need to be considered to limit the impact of nationalistic interests and policies that have been part of the delay in vaccine distribution in some countries. The ultimate objective of a vaccine policy is a speedy and efficient administration of vaccines in the population, not national production, even if the latter is a desirable goal for politicians.
Subjects: 
COVID-19
vaccines
Global Value Chains
multinationals
global supply chains
Asia-Pacific
JEL: 
F10
F23
I18
Document Type: 
Working Paper

Files in This Item:
File
Size
832.53 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.